SEC filing · 8-K

Apimeds Pharmaceuticals US, Inc.: Executive or director change

Apimeds Pharmaceuticals appointed Eric Sherb as Chief Financial Officer following the resignation of Interim CFO Erick Frim.

Filed October 1, 2026

Neutral news

What happened

On September 29, 2026, Erick Frim resigned as Interim Chief Financial Officer without any disagreement with the company.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Apimeds Pharmaceuticals US, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.